Outcomes and side effects after first-line treatment with combination therapies for kidney cancer

This report looked at the results from 4 studies comparing sunitinib with various immunotherapy combinations: nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabozantinib and pembrolizumab/lenvatinib. Overall survival time, time to when the cancer started growing again and the treatment stopped working (progression-free survival), response to treatment in terms of the cancer getting smaller, and side effects to treatment were all […]

read more

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer

Non-clear cell RCC is about 20-25% of all RCC diagnoses and usually has worse survival outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have been shown to help patients with non-clear cell RCC. KEYNOTE-427 is a phase 2 study that looked at the treatment of people with RCC with pembrolizumab as their […]

read more

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer

KEYNOTE-427 is an open-label, single-arm, phase II study to look at the effectiveness of pembrolizumab as a first-line treatment for people with advanced clear cell RCC. At ESMO this year, updated efficacy, and safety results after a minimum follow-up of 41 months were presented. This study looked at the treatment of people with RCC with […]

read more

ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up

The use of two medicines together (combination therapies) for previously untreated patients with RCC that has spread (metastatic RCC) is fast becoming standard treatment for these patients. A study called CheckMate-214 showed that a combination of the immune checkpoint inhibitors nivolumab plus ipilimumab helped patients with intermediate or high risk RCC live longer than those […]

read more

ESMO 2021: Pembrolizumab as adjuvant therapy

Adjuvant therapy is medication that is given in addition to surgery to try to prevent the cancer from coming back. Adjuvant therapy can be used to kill any remaining microscopic cancer cells, or it can control the growth of any remaining cancer. Nephrectomy is the standard of care for renal cell carcinoma; however, the cancer can […]

read more

ESMO 2021: Belzutifan (MK-6482) plus cabozantinib for advanced clear cell RCC

Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in several changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks the action of HIF-2α. This […]

read more

ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)

Ipilimumab plus nivolumab is a standard first-line treatment for patients with intermediate and poor-risk advanced RCC. Serious or life-threatening side effects are relatively common with this combination. The aim of this phase 2 trial (PRISM) was to see if changing the treatment schedule for ipilimumab in combination with nivolumab can improve tolerability of this treatment […]

read more

ESMO 2021: TKI treatment breaks for advanced/metastatic kidney cancer – the STAR study

There is increasing interest in using treatment breaks to reduce side effects without affecting outcomes. This phase 3 trial (STAR) was designed to see how a break in tyrosine kinase inhibitor (TKI) treatment compared to standard first-line treatment with TKIs for people with advanced renal cell carcinoma (RCC). Overall survival time and economic evaluation (quality […]

read more

Patient leaders join new pharmaceutical industry Patient Advisory Council

The Association of the British Pharmaceutical Industry (ABPI) have formed a new Patient Advisory Council including eight leaders from across the patient and health charity sector. The new Council will bring together industry and patient advocates to help bring the patient voice to the ABPI’s plans to ensure a more patient-centred future strategy, policy, and […]

read more

Cabozantinib in pretreated patients with sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to anti-angiogenic targeted therapy, such as sunitinib and pazopanib. This real […]

read more
Showing 1 to 10 of 522 results
  TOP